EpCAM

Ongoing clinical trials and approved products targeting EpCAM, in radioligand therapy and PET/SPECT imaging. Data as of 26 October 2026.

0ongoing therapy trials

2ongoing imaging trials

0approved products

Target note

Full name: Epithelial cell adhesion molecule (EpCAM)
Nature: Transmembrane glycoprotein highly expressed in carcinomas.
Normal expression: Normal epithelia (baseline expression).
Value: A carcinoma target, explored with scaffold proteins (DARPins) with fast pharmacokinetics.
Approaches: [99mTc]- and [123I]-DARPin Ec1.
Indications explored: Breast, ovarian and colorectal cancers (phase 1).
Points of caution: Renal uptake of small proteins.

Trial	Phase	Status	Sponsor	Countries
EpCam-Scan · DARPin Ec1 (EpCAM)NCT07784660 · Breast	Phase 1	By invitation	Tomsk National Research Medical Center of the Russian Academy of Sciences	1
DARPin Ec1 (EpCAM)NCT07400263 · Solid tumors (multiple indications)	No phase	Recruiting	Peking University People's Hospital	1

EpCAM. Theranostic Atlas, LaRadiopharmacie.fr. Data as of 26 October 2026. https://theranosticatlas.com/target/epcam/ (accessed [date]).

A monitoring tool with no regulatory value: check every item at its source.